Equities

Microbot Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Microbot Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.49
  • Today's Change-0.035 / -1.39%
  • Shares traded979.16k
  • 1 Year change+126.94%
  • Beta1.1568
Data delayed at least 15 minutes, as of Jul 15 2025 20:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.67m
  • Incorporated1988
  • Employees21.00
  • Location
    Microbot Medical Inc175 Derby St Bld 27HINGHAM 02043United StatesUSA
  • Phone+1 (781) 875-3605
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Metagenomi Inc45.26m-77.95m84.11m176.00--0.3955--1.86-2.11-2.111.235.690.1269--29.26224,074.30-21.86---25.87-------172.21------0.00--16.84---14.36------
Oramed Pharmaceuticals, Inc.2.00m-28.24m87.01m13.00--0.6179--43.51-0.6941-0.69410.04873.450.0114----153,846.20-16.10---18.01--0.65---1,413.95-----1.400.00---100.00---444.98------
XBiotech Inc0.00-39.41m88.11m90.00--0.5043-----1.29-1.290.005.730.00----0.00-19.24-7.74-20.35-8.02-------187.68----0.00-------56.90--44.92--
Veru Inc10.61m-29.16m88.61m210.00--4.21--8.35-0.1992-0.24830.07250.14360.2031----50,525.67-55.83-47.99-65.32-60.8837.9469.58-274.84-128.45---71.120.00--3.62-11.8959.42--7.85--
Acumen Pharmaceuticals Inc0.00-116.25m90.25m61.00--0.5803-----1.93-1.930.002.570.00----0.00-46.00-33.77-48.68-35.61-------21,273.47----0.1596-------95.39------
Microbot Medical Inc0.00-11.67m91.67m21.00--3.02-----0.6422-0.64220.000.83330.00----0.00-61.02-67.69-66.36-80.15------------0.00-------6.55---35.03--
Beyondspring Inc-100.00bn-100.00bn92.32m40.00---------------0.7022-----------61.84---81.30-------6,633.90------------35.26--123.69--
Jupiter Neurosciences Inc0.00-3.33m93.02m4.00--30.35-----0.104-0.1040.000.0926------0.00---383.24-----------902.90---20.740.0456------49.00------
Climb Bio Inc0.00-92.98m95.96m17.00--0.4962-----2.37-2.370.002.860.00----0.00-59.97-39.53-61.97-41.05------------0.00-------110.42------
Contineum Therapeutics Inc0.00-49.83m96.50m41.00--0.5223-----1.93-1.930.007.140.00----0.00-30.97---32.50--------------0.00---100.00---285.99------
Zentalis Pharmaceuticals Inc26.87m-224.19m97.85m166.00--0.3313--3.64-3.15-3.150.37694.110.0571--9.12161,837.30-47.62-43.59-53.55-49.56-----834.49-1,402.74---16.480.00------43.24---8.89--
Outlook Therapeutics Inc0.0021.12m97.89m23.001.94--4.61--1.201.200.00-0.98650.00----0.0054.08-228.57---4,956.74--------0.5722--56.74-------27.78------
Vaxart Inc47.40m-58.12m98.14m105.00--2.15--2.07-0.2721-0.27210.21850.19990.3834--5.68451,380.90-47.02-49.90-86.36-58.33-----122.63-875.06---87.400.0757--288.9423.8218.82---8.21--
Nautilus Biotechnology Inc0.00-68.66m99.37m134.00--0.5111-----0.5464-0.54640.001.540.00----0.00-26.60-20.34-27.52-20.82------------0.00-------11.16--18.04--
MacroGenics Inc154.05m-55.81m99.68m341.00--1.26--0.6471-0.8899-0.88992.451.250.65162.9217.35451,759.50-23.61-33.40-30.87-40.6089.88---36.23-97.173.11-1,362.340.00--155.2618.50-639.30---2.88--
Data as of Jul 15 2025. Currency figures normalised to Microbot Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

5.38%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2025738.20k2.13%
Geode Capital Management LLCas of 31 Mar 2025316.92k0.91%
BlackRock Fund Advisorsas of 31 Mar 2025236.11k0.68%
SSgA Funds Management, Inc.as of 31 Mar 2025136.67k0.39%
DNB Asset Management ASas of 31 Mar 2025114.82k0.33%
Susquehanna Financial Group LLLPas of 31 Mar 2025104.18k0.30%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202571.06k0.21%
Two Sigma Investments LPas of 31 Mar 202568.20k0.20%
Envestnet Asset Management, Inc.as of 31 Mar 202541.74k0.12%
UBS Securities LLCas of 31 Mar 202541.13k0.12%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.